# Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects

> **NCT02378506** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 188 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **BIOLOGICAL:** etanercept

## Key facts

- **NCT ID:** NCT02378506
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-05
- **Final completion:** 2016-06
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02378506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02378506, "Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02378506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*